biOasis Secures DTC Eligibility

biOasis Technologies Inc. (OTCQX:BIOAF) (TSX VENTURE:BTI), a pioneering
biopharmaceutical company focused on overcoming the limitations of therapeutic
drug delivery across the blood-brain barrier, today announced that it has
secured DTC eligibility by The Depository Trust Company (DTC) for its shares
traded on the OTCQX(R) under the symbol BIOAF.


The DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC),
and manages the electronic clearing and settlement of publicly traded companies.
Securities that are eligible to be electronically cleared and settled through
the DTC are considered "DTC eligible." This electronic method of clearing
securities speeds up the receipt of stock and cash, and thus accelerates the
settlement process for investors and brokers.


"DTC eligibility increases the efficiency and lowers the cost associated of
trading BIOAF on the OTCQX, while increasing security and lowering transaction
risk for our investors," said Rob Hutchison, president and CEO of biOasis.
"Securing DTC eligibility reflects our ongoing efforts to support our growing
investor base in the U.S."


About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the OTCQX under the symbol, BIOAF, and on the TSX Venture
Exchange under the symbol, BTI. For more information about the company please
visit www.bioasis.ca.


Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not succeed in
preclinical or clinical trials, or future products in our targeted corporate
objectives; our future operating results are uncertain and likely to fluctuate;
we may not be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching our products
may be greater than anticipated; we have no experience in commercial
manufacturing; we may face unknown risks related to intellectual property
matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given these risks
and uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements and
information made herein are based on our current expectations and we undertake
no obligation to revise or update such forward- looking statements and
information to reflect subsequent events or circumstances, except as required by
law.


On Behalf of the Board of Directors

Rob Hutchison Chairman & CEO 

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
778-383-3280
rob@bioasis.ca


Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Senior Managing Director
949-574-3860
BTI@liolios.com
BiOasis Technologies (TSXV:BTI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024